SGLT2 inhibitors have been shown to have a significant benefit for patients with DM2 or CAD (DAPA-HF, Emperor-reduced) The usage of these medications are low compared to other Goal Directed Medical Therapy. There are multiple contributing factors as to why these medications are underutilized
Our aim is to assess barriers against prescription of SGLT2-i at the time of discharge from TJUH and to increase utilization after placement on formulary